NIH Funding Threats & Special Diabetes Program – Senate Appropriations Hearing Notes

U.S. Senate Appropriations Committee hearing; unusually large, “standing-room-only” audience (overflow room acknowledged).
Focus: NIH funding, Special Diabetes Program (SDP), and NIDDK-supported Type 1 Diabetes (T1D) research.
Key speakers referenced
- Senator (chair; name not stated in excerpt) – opens session, frames urgency.
- Senator Durbin – previously outlined NIH funding history & current threats.
- Senator Moran & Chairman Collins – acknowledged near close.
- Witnesses
- Katie (T1D patient-advocate, athlete) – provides lived-experience testimony.
- Dr. Rogers (likely Dr. Griffin P. Rodgers, Director of NIDDK) – answers on grant impact.
- Dr. Bhattacharya (NIH Acting Director Dr. M. Bhattacharya) – cited from earlier hearing for forward-funding plan.

“Tremendous progress” in new & better treatments; advocates credited for pushing Congress to expand NIH/NIDDK budgets.
Each advancement viewed as “every day we are closer to a cure.”
Special Diabetes Program singled out as catalyst for many breakthroughs.

Year-to-date NIH spending shortfalls (compared with previous fiscal year):
- By March → $1{,}700{,}000{,}000$ less.
- By mid-May → $3{,}000{,}000{,}000$ less.
- By June → nearly $6{,}000{,}000{,}000$ less.
NIH internal plan: award $40\%$ fewer new grants in current FY.
Cause compounded by proposed “forward-funding” model: funding ≈ $50\%$ of a multi-year grant upfront in first year, consuming appropriations rapidly and slashing overall grant count “by the thousands.”
Risk: NIH could either under-spend Congressionally appropriated dollars or rush them out via forward-funding, creating larger cliff next year.

Q: “How will diabetes research be affected if NIDDK awards $40\%$ fewer grants?”
Dr. Rogers’ responses
- Commitment to fully spend Congressional dollars.
- Notes SDP budget is extended in the President’s budget (i.e., protected line-item separate from base appropriation).
- Reiterates NIH Director’s (Dr. Bhattacharya) pledge that U.S. remains global R&D leader.
- Stresses need for ongoing Congressional-executive dialogue to adjust budgets.
- More funds ⇒ more progress; cites SDP as example of effectiveness.

Definition: Provide ~ $50\%$ of multi-year award in Year 1, leaving diminished funds for new starts in Years 2–4.
Potential impact (Committee’s view):
- “Devastating cuts” to both current-year and out-year research portfolios.
- Could be implemented unilaterally by NIH unless Congress blocks/conditions it.

Patients’ timeline to cure directly tied to grant volume and continuity.
Research workforce: Fewer grants → lab closures, talent loss, slower innovation.
Global leadership: Funding retreat risks ceding biomedical edge to other nations.
Moral duty: Legislators confronted with concrete patient stories illustrating real-world stakes of budget lines.

NIH budget doubling (1998-2003) & subsequent stagnation referenced implicitly by Sen. Durbin.
SDP repeatedly renewed by bipartisan coalitions; serves as model for disease-focused, time-limited funding.

Grant reduction target: $40\%$ fewer.
Spending shortfalls: $1{,}700{,}000{,}000$ → $3{,}000{,}000{,}000$ → $6{,}000{,}000{,}000$ .
Forward-funding front-load: $50\%$ of award value in Year 1.

Monitor Congressional negotiations re: FY appropriations & forward-funding language.
Emphasize patient narratives (e.g., Katie’s) when lobbying.
Highlight quantitative impacts (billions underspent, percent grant cuts) to policymakers.

Analyze pros/cons of forward-funding multi-year grants within constrained budgets.
Evaluate ethical responsibility of federal funding agencies to maintain consistent research pipelines.
Propose alternative budget strategies to safeguard disease-specific programs like SDP while sustaining broad NIH grant numbers.